Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Falls 7% – What’s Next?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)’s share price was down 7% during mid-day trading on Tuesday. The stock traded as low as $18.81 and last traded at $18.84. 119,287 shares changed hands during trading, a decline of 72% from the average session volume of 429,429 shares. The stock had previously closed at $20.25.

Analysts Set New Price Targets

A number of equities analysts have commented on DMRA shares. Wall Street Zen raised shares of Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a research note on Sunday. Wedbush restated an “outperform” rating and set a $40.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, September 29th. Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Damora Therapeutics, Inc. Common Stock has a consensus rating of “Buy” and a consensus target price of $46.50.

Damora Therapeutics, Inc. Common Stock Trading Down 6.9%

The stock has a market capitalization of $1.16 billion, a PE ratio of -5.59 and a beta of 1.43. The business has a fifty day moving average price of $26.38 and a 200-day moving average price of $25.92.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. On average, equities analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Insider Transactions at Damora Therapeutics, Inc. Common Stock

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett purchased 12,500 shares of Damora Therapeutics, Inc. Common Stock stock in a transaction on Friday, September 25th. The shares were acquired at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the completion of the transaction, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. The trade was a 2.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 0.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds have recently made changes to their positions in the business. Arizona State Retirement System purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $260,000. Squarepoint Ops LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at $303,000. Seven Fleet Capital Management LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at $7,398,000. Finally, Braidwell LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at $42,146,000. 14.20% of the stock is currently owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.